

Anti-MCC Antibody
Catalog # ABO11609**Specification**

Anti-MCC Antibody - Product Information

Application	WB
Primary Accession	P23508
Host	Rabbit
Reactivity	Human, Mouse, Rat
Clonality	Polyclonal
Format	Lyophilized

Description

Rabbit IgG polyclonal antibody for Colorectal mutant cancer protein(MCC) detection. Tested with WB in Human;Mouse;Rat.

Reconstitution

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

Anti-MCC Antibody - Additional Information

Gene ID 4163

Other Names

Colorectal mutant cancer protein, Protein MCC, MCC

Calculated MW

93027 MW KDa

Application Details

Western blot, 0.1-0.5 µg/ml, Human, Mouse, Rat

Subcellular Localization

Cell membrane. Cell projection, lamellipodium. Nucleus . Cytoplasm . Colocalizes with actin at the leading edge of polarized cells.

Tissue Specificity

Expressed in a variety of tissues.

Protein Name

Colorectal mutant cancer protein

Contents

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na₂HPO₄, 0.05mg Thimerosal, 0.05mg NaN₃.

Immunogen

A synthetic peptide corresponding to a sequence at the C-terminus of human MCC(573-590aa IQQLKNDRAAVKLTMLEL), identical to the related mouse and rat sequences.

Purification

Immunogen affinity purified.

Cross Reactivity

No cross reactivity with other proteins

Storage

At -20°C for one year. After r°Constitution, at 4°C for one month. It°Can also be aliquotted and stored frozen at -20°C for a longer time.Avoid repeated freezing and thawing.

Anti-MCC Antibody - Protein Information**Name** MCC**Function**

Candidate for the putative colorectal tumor suppressor gene located at 5q21. Suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. Inhibits DNA binding of b-catenin/TCF/LEF transcription factors. Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase (PAK) activation (PubMed:18591935, PubMed:19555689, PubMed:22480440). Represses the beta-catenin pathway (canonical Wnt signaling pathway) in a CCAR2- dependent manner by sequestering CCAR2 to the cytoplasm, thereby impairing its ability to inhibit SIRT1 which is involved in the deacetylation and negative regulation of beta-catenin (CTNB1) transcriptional activity (PubMed:24824780).

Cellular Location

Cell membrane. Cell projection, lamellipodium. Nucleus. Cytoplasm. Note=Colocalizes with actin at the leading edge of polarized cells


Tissue Location


Expressed in a variety of tissues.

Anti-MCC Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-MCC Antibody - Images



Anti-MCC antibody, ABO11609, All Western blotting All lanes: Anti-MCC(ABO11609) at 0.5ug/ml Lane 1: Rat Brain Tissue Lysate at 40ug Lane 2: 293T Whole Cell Lysate at 40ug Lane 3: NIH Whole Cell Lysate at 40ug Lane 4: A549 Whole Cell Lysate at 40ug Lane 5: HEPG2 Whole Cell Lysate at 40ug Predicted bind size: 93KD Observed bind size: 93KD

Anti-MCC Antibody - Background

MUTATED IN COLORECTAL CANCERS(MCC) is a tumor suppressor gene. It is mapped to 5q22.2. This gene suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. MCC also Inhibits DNA binding of b-catenin/TCF/LEF transcription factors, and it is Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase(PAK) activation. What's more, MCC can interact with SCRIB(via phosphorylated PDZ-binding motif), EZR, SNX27, SLC9A3R1 and SLC9A3R2.